---
title: "Key facts: GALT: Belapectin lowers stiffness; funding May 2027; Q1 loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286637622.md"
description: "Galectin Therapeutics (GALT) reports Phase 2b/3 NAVIGATE analysis: belapectin 2 mg/kg showed significant liver stiffness reductions at Weeks 26, 52, 78 and fewer patients worsened versus placebo.1GALT says cash plus credit will fund operations through May 2027; company warns it will need additional capital after that date.2Galectin Therapeutics (GALT) posted an adjusted loss per share of $0.08 for Q1, zero revenue, a $5.56M net loss; shares fell 15.8% in the quarter and 43.5% YTD.3"
datetime: "2026-05-16T07:14:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286637622.md)
  - [en](https://longbridge.com/en/news/286637622.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286637622.md)
---

# Key facts: GALT: Belapectin lowers stiffness; funding May 2027; Q1 loss

-   Galectin Therapeutics (GALT) reports Phase 2b/3 NAVIGATE analysis: belapectin 2 mg/kg showed significant liver stiffness reductions at Weeks 26, 52, 78 and fewer patients worsened versus placebo.1
-   GALT says cash plus credit will fund operations through May 2027; company warns it will need additional capital after that date.2
-   Galectin Therapeutics (GALT) posted an adjusted loss per share of $0.08 for Q1, zero revenue, a $5.56M net loss; shares fell 15.8% in the quarter and 43.5% YTD.3

### Related Stocks

- [GALT.US](https://longbridge.com/en/quote/GALT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Galectin Therapeutics Q2 FY26 net loss widens 21.17% to $9.11 million](https://longbridge.com/en/news/295930000.md)
- [Galectin chair Uihlein receives 34,376,167 shares in debt-to-equity conversion](https://longbridge.com/en/news/294818966.md)
- [Galectin, FDA agree on late-stage trial design for MASH therapy](https://longbridge.com/en/news/290567199.md)
- [Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension](https://longbridge.com/en/news/292638312.md)
- [Galectin Therapeutics CMO Jamil Khurram disposes of common shares worth $262,943](https://longbridge.com/en/news/291343337.md)